Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 1.200
Filtrar
1.
Bratisl Lek Listy ; 121(2): 154-158, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32115970

RESUMO

OBJECTIVE: This study aimed to evaluate the effect of Coenzyme Q10 (CoQ10) administration to patients in the early phase of sepsis to determine its effect on the markers of inflammation and the clinical outcomes of septic patients. BACKGROUND: Previous studies showed that CoQ10 levels were decreased in septic patients and worsening of mitochondrial dysfunction was observed. METHODS: In this randomized controlled trial septic patients (n=40) received 100 mg CoQ10 twice a day for seven days added to standard treatment of sepsis. As a primary endpoint levels of Interleukin 6 (IL-6), Tumor Necrosis Factor-α (TNF-α), Glutathione peroxidase and malondialdehyde (MDA) were assessed at baseline, third and 7th day after the intervention. Secondary endpoints included assessment of clinical scores and     in-hospital mortality. RESULTS: There was no difference in baseline inflammatory and oxidative injury markers between the groups. TNF-α and MDA levels decreased significantly in the CoQ10 group on the 7th day of the study (P:0.003 for both). There was a significant difference in the in-hospital mortality in the CoQ10 group compared to the control group (P:0.01). CONCLUSION: These findings suggest that CoQ10 has a positive effect on clinical parameters as well as mitochondrial dysfunction when administered in the early phase of sepsis (Tab. 2, Fig. 1, Ref. 38).


Assuntos
Inflamação , Sepse , Ubiquinona/análogos & derivados , Biomarcadores , Método Duplo-Cego , Humanos , Inflamação/tratamento farmacológico , Malondialdeído , Sepse/tratamento farmacológico , Sepse/imunologia , Ubiquinona/uso terapêutico
2.
Methodist Debakey Cardiovasc J ; 15(3): 185-191, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31687097

RESUMO

Coenzyme Q10 (CoQ10) is among the most widely used dietary and nutritional supplements on the market. CoQ10 has several fundamental properties that may be beneficial in several clinical situations. This article reviews the pertinent chemical, metabolic, and physiologic properties of CoQ10 and the scientific data and clinical trials that address its use in two common clinical settings: statin-associated myopathy syndrome (SAMS) and congestive heart failure (CHF). Although clinical trials of CoQ10 in SAMS have conflicting conclusions, the weight of the evidence, as seen in meta-analyses, supports the use of CoQ10 in SAMS overall. In CHF, there is a lack of large-scale randomized clinical trial data regarding the use of statins in patients receiving contemporary treatment. However, one relatively recent randomized clinical trial, Q-SYMBIO, suggests an adjunctive role for CoQ10 in CHF. Recommendations regarding the use of CoQ10 in these clinical situations are presented.


Assuntos
Antioxidantes/uso terapêutico , Suplementos Nutricionais , Insuficiência Cardíaca/tratamento farmacológico , Inibidores de Hidroximetilglutaril-CoA Redutases/efeitos adversos , Ubiquinona/análogos & derivados , Animais , Antioxidantes/efeitos adversos , Antioxidantes/farmacocinética , Suplementos Nutricionais/efeitos adversos , Metabolismo Energético/efeitos dos fármacos , Insuficiência Cardíaca/diagnóstico , Insuficiência Cardíaca/epidemiologia , Insuficiência Cardíaca/metabolismo , Humanos , /epidemiologia , Estresse Oxidativo/efeitos dos fármacos , Fatores de Risco , Síndrome , Resultado do Tratamento , Ubiquinona/efeitos adversos , Ubiquinona/farmacocinética , Ubiquinona/uso terapêutico
3.
Adv Exp Med Biol ; 1178: 103-112, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31493224

RESUMO

Coenzyme Q10 (CoQ10) is a vitamin-like substance which functions as an electron carrier within the mitochondrial respiratory chain, as well as serving as an important intracellular antioxidant. Most of the body's CoQ10 requirements are met by endogenous synthesis, although the capacity for CoQ10 production decreases substantially with increasing age. In this article we have reviewed the potential role of CoQ10 supplementation in the treatment of tissue fibrosis, which has been implicated in the age-related loss of function of various organs including the heart. Clinical studies have indicated that CoQ10 supplementation may decrease the level of cardiovascular fibrosis to which older individuals are subjected, and thereby improve cardiovascular function and reduce the risk of cardiovascular associated mortality. Although the factors responsible for the anti-fibrotic action of CoQ10 have yet to be fully elucidated, its antioxidant and anti-inflammatory functions are thought to be major contributors to its clinical efficacy in the treatment of this age-related disorder.


Assuntos
Antioxidantes , Ubiquinona/análogos & derivados , Antioxidantes/uso terapêutico , Doenças Cardiovasculares/tratamento farmacológico , Doenças Cardiovasculares/patologia , Fibrose/tratamento farmacológico , Humanos , Ubiquinona/uso terapêutico
4.
Perm J ; 232019.
Artigo em Inglês | MEDLINE | ID: mdl-31496499

RESUMO

CONTEXT: Heart failure (HF) is rapidly increasing in incidence and is often present in patients receiving long-term statin therapy. OBJECTIVE: To test whether or not patients with HF on long-term statin therapy respond to discontinuation of statin therapy and initiation of coenzyme Q10 (CoQ10) supplementation. DESIGN: We prospectively identified patients receiving long-term statin therapy in whom HF developed in the absence of any identifiable cause. Treatment consisted of simultaneous statin therapy discontinuation and CoQ10 supplementation (average dosage = 300 mg/d). MAIN OUTCOME MEASURES: Baseline and follow-up physical examination findings, symptom scores, echocardiograms, and plasma CoQ10 and cholesterol levels. RESULTS: Of 142 identified patients with HF, 94% presented with preserved ejection fraction (EF) and 6% presented with reduced EF (< 50%). After a mean follow-up of 2.8 years, New York Heart Association class 1 increased from 8% to 79% (p < 0.0001). In patients with preserved EF, 34% had normalization of diastolic function and 25% showed improvement (p < 0.0001). In patients with reduced EF at baseline, the EF improved from a mean of 35% to 47% (p = 0.02). Statin-attributable symptoms including fatigue, muscle weakness, myalgias, memory loss, and peripheral neuropathy improved (p < 0.01). The 1-year mortality was 0%, and the 3-year mortality was 3%. CONCLUSION: In patients receiving long-term statin therapy, statin-associated cardiomyopathy may develop that responds safely to statin treatment discontinuation and CoQ10 supplementation. Statin-associated cardiomyopathy may be a contributing factor to the current increasing prevalence of HF with preserved EF.


Assuntos
Cardiomiopatias/induzido quimicamente , Inibidores de Hidroximetilglutaril-CoA Redutases/efeitos adversos , Ubiquinona/análogos & derivados , Idoso , Cardiomiopatias/tratamento farmacológico , Cardiomiopatias/fisiopatologia , Colesterol/sangue , Feminino , Insuficiência Cardíaca/induzido quimicamente , Insuficiência Cardíaca/tratamento farmacológico , Insuficiência Cardíaca/fisiopatologia , Humanos , Masculino , Volume Sistólico , Ubiquinona/sangue , Ubiquinona/uso terapêutico , Vitamina E/sangue
5.
Med Arch ; 73(2): 109-112, 2019 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-31391698

RESUMO

Introduction: Cataract surgery is a widely used procedure around the world. After cataract surgery, one of the important points is that oxidative stress may cause postoperative corneal edema and vision loss. Aim: In this study, we aim to reduce the oxidative stress and related conditions that may develop during intraoperative and postoperative FAKO + IOL implantation. Material and Methods: Total amount of 32 patients with cataract were included to the study. The patients were classified as two groups randomly and the same surgical procedure was applied to the patients in both groups, except using visudrop. Group I was defined as a control group and routine FAKO + IOL implantation surgery was performed. In Group II, after the sideport was opened at the beginning of the operation, 0.5 cc visudrop (coenzyme q + vitamin E + hypermellosis) was given to the anterior camara. After the operation, 0.5 cc visudrop was also given to the anterior camara. Postoperative examination findings were compared statistically. Results: In Group II, postoperative 1st day and postoperative 7th day visual acuities were significantly higher than in Group I. In Group II, postoperative 1st day and postoperative 7th day visual acuity increments were significantly higher than in Group I. In Group I, postoperative 1st day and 7th day pachymetry value increments were significantly higher than in Group II. Conclusion: Using visudrop during the FAKO + IOL implantation may be an effective method for postoperative corneal edema and vision.


Assuntos
Antioxidantes/uso terapêutico , Implante de Lente Intraocular/métodos , Micronutrientes/uso terapêutico , Facoemulsificação/métodos , Cuidados Pós-Operatórios/métodos , Ubiquinona/uso terapêutico , Vitamina E/uso terapêutico , Administração Oftálmica , Idoso , Idoso de 80 Anos ou mais , Edema da Córnea/epidemiologia , Paquimetria Corneana , Feminino , Humanos , Cuidados Intraoperatórios/métodos , Masculino , Pessoa de Meia-Idade , Estresse Oxidativo , Complicações Pós-Operatórias/epidemiologia , Tonometria Ocular
6.
Free Radic Res ; 53(8): 901-909, 2019 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-31387429

RESUMO

Although coenzyme Q10 (CoQ10) supplementation has shown to reduce pain levels in chronic pain, the effects of CoQ10 supplementation on pain, anxiety, brain activity, mitochondrial oxidative stress, antioxidants, and inflammation in pregabalin-treated fibromyalgia (FM) patients have not clearly elucidated. We hypothesised that CoQ10 supplementation reduced pain better than pregabalin alone via reducing brain activity, mitochondrial oxidative stress, inflammation, and increasing antioxidant levels in pregabalin-treated FM patients. A double-blind randomised placebo-controlled trial was conducted. Eleven FM patients were enrolled with 2 weeks wash-out then randomly allocated to 2 treatment groups; pregabalin with CoQ10 or pregabalin with placebo for 40 d. Then, patients in CoQ10 group were switched to placebo, and patients in placebo group were switched to CoQ10 for another 40 d. Pain pressure threshold (PPT), FM questionnaire, anxiety, and pain score were examined. Peripheral blood mononuclear cells (PBMCs) were isolated to investigate mitochondrial oxidative stress and inflammation at day 0, 40, and 80. The level of antioxidants and brain positron emission tomography (PET) scan were also determined at these time points. Pregabalin alone reduced pain and anxiety via decreasing brain activity compared with their baseline. However, it did not affect mitochondrial oxidative stress and inflammation. Supplementation with CoQ10 effectively reduced greater pain, anxiety and brain activity, mitochondrial oxidative stress, and inflammation. CoQ10 also increased a reduced glutathione levels and superoxide dismutase (SOD) levels in FM patients. These findings provide new evidence that CoQ10 supplementation provides further benefit for relieving pain sensation in pregabalin-treated FM patients, possibly via improving mitochondrial function, reducing inflammation, and decreasing brain activity.


Assuntos
Fibromialgia/tratamento farmacológico , Estresse Oxidativo , Dor/tratamento farmacológico , Pregabalina/uso terapêutico , Ubiquinona/análogos & derivados , Adulto , Encéfalo/diagnóstico por imagem , Encéfalo/fisiopatologia , Método Duplo-Cego , Feminino , Fibromialgia/complicações , Fibromialgia/diagnóstico por imagem , Fibromialgia/fisiopatologia , Humanos , Inflamação , Leucócitos Mononucleares/metabolismo , Masculino , Pessoa de Meia-Idade , Mitocôndrias/metabolismo , Dor/etiologia , Tomografia por Emissão de Pósitrons , Ubiquinona/farmacologia , Ubiquinona/uso terapêutico
7.
Arch Med Res ; 50(2): 1-10, 2019 02.
Artigo em Inglês | MEDLINE | ID: mdl-31349945

RESUMO

BACKGROUND: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in reproductive age women. OBJECTIVE: This study was conducted to investigate the effects of CoQ10 and/or vitamin E on cardiometabolic outcomes in patients with PCOS. METHODS: This randomized clinical trial was carried out among 86 women with PCOS. Patients were assigned to take CoQ10, vitamin E, CoQ10 plus vitamin E or placebo for 8 weeks. Fasting blood samples were obtained at the beginning and end of the study. RESULTS: A significant decrease in serum triglycerides (TG) (p <0.001) was found following the administration of CoQ10 and/or vitamin E supplements compared with the placebo group. Supplementation with CoQ10 and vitamin E failed to affect total cholesterol levels. However, co-administration of CoQ10 and vitamin E resulted in a significant decrease in serum total cholesterol levels (9.92 [15.11, 4.74]). Additionally, only the combination of supplements was able to significantly reduce low-density lipoprotein-cholesterol (LDL-C) (‒9.63 [‒15.34, ‒3.92]), increase high-density lipoprotein-cholesterol (HDL-C) (2.33 [0.51, 4.16), reduce atherogenic coefficient (AC) (‒0.29 [‒0.43, ‒0.16], p = 0.03) and decrease visceral adiposity index (VAI) values. Co-Q10 and vitamin E (alone or in combination) had significant effects on non-HDL-C (p = 0.004), atherogenic Index of Plasma (AIP) (p = <0.001) and lipid accumulation product (LAP) (p <0.001) and SBP (p = 0.005). However, the reduction in DBP was statistically significant only for patients who received combined supplementations (p = 0.04). CONCLUSIONS: In conclusion, CoQ10, vitamin E (alone or in combination) had beneficial effects on cardiometabolic outcomes among women with PCOS.


Assuntos
Adiposidade/efeitos dos fármacos , Doenças Cardiovasculares/prevenção & controle , Síndrome do Ovário Policístico/patologia , Ubiquinona/análogos & derivados , Vitamina E/uso terapêutico , Adulto , Doenças Cardiovasculares/sangue , Colesterol/sangue , HDL-Colesterol/sangue , LDL-Colesterol/sangue , Suplementos Nutricionais , Feminino , Humanos , Obesidade Abdominal , Triglicerídeos/sangue , Ubiquinona/uso terapêutico
8.
Medicine (Baltimore) ; 98(24): e15850, 2019 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-31192915

RESUMO

BACKGROUND: The diabetic kidney disease (DKD) has become a seriously kidney disease that commonly caused by diabetes mellitus (DM). Oxidative stress response plays an essential role in the genesis and worsening of DKD and Coenzyme Q10 (CoQ10) has been reported the promising clinical effectiveness on DKD treatment. However, there is lack of relative evidence-based medical evidence currently. OBJECTIVE: The systematic review and meta-analysis was based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, which conducted to evaluate the effectiveness of CoQ10 in combination with other western medicine for DKD therapy through the randomized controlled trials (RCTs) and experimental studies. METHODS: RCTs and experimental studies were searched based on standardized searching rules in 12 medical databases from the inception up to June 2018 and a total of 8 articles (4 RCTs and 4 experimental studies) were enrolled in the meta-analysis. RESULTS: The results revealed that CoQ10 combined with other western medicine show statistical differences in the laboratory parameters of fasting plasma glucose (FPG), Hemoglobin A1c (HbA1c), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), triglyceride (TG), and malondialdehyde (MDA) amelioration after DKD therapy compared with control group. However, LDL-C and Urea level for RCTs and Urine output and Glucose for experimental studies on DKD was not superior to control group. CONCLUSION: We need to make conclusion cautiously for the effectiveness of CoQ10 application on DKD therapy. More standard, multicenter, double-blind RCTs, and formal experimental studies of CoQ10 treatment for DKD were urgent to be conducted for more clinical evidence providing in the future. The underlying pharmacological mechanism of CoQ10 needs to be researched and revealed for its future application on DKD therapy.


Assuntos
Nefropatias Diabéticas/tratamento farmacológico , Ubiquinona/análogos & derivados , Vitaminas/uso terapêutico , Glicemia/metabolismo , Colesterol/metabolismo , Nefropatias Diabéticas/metabolismo , Medicina Baseada em Evidências , Hemoglobina A Glicada/metabolismo , Humanos , Estudos Multicêntricos como Assunto , Ensaios Clínicos Controlados Aleatórios como Assunto , Resultado do Tratamento , Ubiquinona/uso terapêutico
9.
Molecules ; 24(9)2019 May 07.
Artigo em Inglês | MEDLINE | ID: mdl-31067711

RESUMO

As a new dosage form, coenzyme Q10 (Co-Q10) soft capsules are easily absorbed and utilized by the human body. Co-Q10 soft capsules can effectively improve the bioavailability and reduce medical costs for patients. A main concern about Co-Q10 as an active pharmaceutical ingredient (API) is how to control the total quantity of related substances. In this article, according to the degradation pattern of the API, the most easily degradable impurity (impurity X) in the sample was prepared and its chemical structure was determined. Furthermore, a simple and accurate method was developed for the determination of related substances and to avert the interference of excipient ingredients in Co-Q10 soft capsules. The approach was validated adequately and the primary impurity X was confirmed accurately. The limit of total quantity of related substances (less than 1%) could be revised to the level of specific impurity X being no more than 0.5%, in this effective quality control method of Co-Q10 soft capsules. The revised level is suggested to be included in the corresponding standard of the supplement taken from the Pharmacopoeia of the People's Republic of China (2015 edition). This can provide a feasible method for the relevant enterprises and regulatory authorities to control the related substances of coenzyme Q10 soft capsules.


Assuntos
Antioxidantes/química , Cápsulas/química , Composição de Medicamentos , Ubiquinona/análogos & derivados , Antioxidantes/uso terapêutico , Disponibilidade Biológica , Cápsulas/uso terapêutico , China , Suplementos Nutricionais , Humanos , Ubiquinona/química , Ubiquinona/uso terapêutico
11.
Oxid Med Cell Longev ; 2019: 3061607, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30984333

RESUMO

The main reasons for the inefficiency of standard glioblastoma (GBM) therapy are the occurrence of chemoresistance and the invasion of GBM cells into surrounding brain tissues. New therapeutic approaches obstructing these processes may provide substantial survival improvements. The purpose of this study was to assess the potential of lipophilic antioxidant coenzyme Q10 (CoQ10) as a scavenger of reactive oxygen species (ROS) to increase sensitivity to temozolomide (TMZ) and suppress glioma cell invasion. To that end, we used a previously established TMZ-resistant RC6 rat glioma cell line, characterized by increased production of ROS, altered antioxidative capacity, and high invasion potential. CoQ10 in combination with TMZ exerted a synergistic antiproliferative effect. These results were confirmed in a 3D model of microfluidic devices showing that the CoQ10 and TMZ combination is more cytotoxic to RC6 cells than TMZ monotherapy. In addition, cotreatment with TMZ increased expression of mitochondrial antioxidant enzymes in RC6 cells. The anti-invasive potential of the combined treatment was shown by gelatin degradation, Matrigel invasion, and 3D spheroid invasion assays as well as in animal models. Inhibition of MMP9 gene expression as well as decreased N-cadherin and vimentin protein expression implied that CoQ10 can suppress invasiveness and the epithelial to mesenchymal transition in RC6 cells. Therefore, our data provide evidences in favor of CoQ10 supplementation to standard GBM treatment due to its potential to inhibit GBM invasion through modulation of the antioxidant capacity.


Assuntos
Antioxidantes/uso terapêutico , Neoplasias Encefálicas/tratamento farmacológico , Glioblastoma/tratamento farmacológico , Temozolomida/uso terapêutico , Ubiquinona/análogos & derivados , Animais , Neoplasias Encefálicas/patologia , Resistencia a Medicamentos Antineoplásicos , Glioblastoma/patologia , Humanos , Masculino , Camundongos , Ratos Wistar , Temozolomida/farmacologia , Ubiquinona/farmacologia , Ubiquinona/uso terapêutico
12.
Complement Ther Med ; 43: 181-187, 2019 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-30935528

RESUMO

AIMS: A number of studies have examined the beneficial effects of Coenzyme Q10 (CoQ10) on fatigue in different population, but the findings have been inconclusive. Herein, we systematically reviewed available interventional studies to elucidate the overall effects of CoQ10 supplementation on fatigue among adolescent and adult population. METHODS: PubMed, Cochrane's library, Science direct, Scopus, Google scholar and ISI web of science databases were searched for all available literature until April 2018 for studies assessing the effects of CoQ10 supplementation on fatigue. The Cochrane bias assessment tool were used to assess the quality of studies. RESULTS: A total of 16 studies out of 1316 met our inclusion criteria and included in our systematic review. Among included studies 10 of them showed significant beneficial effects (p < 0.05) of CoQ10 supplementation on fatigue status among healthy, fibromyalgia, statin-related fatigue, multiple sclerosis and end-stage heart failure subjects. CoQ10 supplementation could alleviate fatigue, but differences between studies population should be taken into account. CONCLUSION: It seems CoQ10 has better therapeutic effects in statin-related fatigue and fibromyalgia patients compared with the other disease related fatigue. Finally, in order to draw a firm link between CoQ10 and fatigue, more clinical trials with adequate sample size and with sufficient follow-up periods are needed.


Assuntos
Fadiga/tratamento farmacológico , Ubiquinona/análogos & derivados , Suplementos Nutricionais , Humanos , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Terapia Nutricional/métodos , Ubiquinona/uso terapêutico
13.
J Med Case Rep ; 13(1): 63, 2019 Mar 06.
Artigo em Inglês | MEDLINE | ID: mdl-30837005

RESUMO

BACKGROUND: Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes, the most common maternally inherited mitochondrial disease, can present with a wide range of neurological manifestations including both central and peripheral nervous system involvement. The most frequent genetic mutation reported in mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome is A3243G in MT-TL1 gene. Stroke-like episodes, dementia, epilepsy, lactic acidemia, myopathy, recurrent headaches, hearing impairment, diabetes, and short stature constitute the known presentations in this syndrome. Among the abnormal involuntary movements in mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome, myoclonus is the commonest. Other movement disorders, including chorea, are rarely reported in this disorder. CASE PRESENTATION: A 14-year-old South Asian boy from rural Bengal (India), born of a second degree consanguineous marriage, with normal birth and development history, presented with abnormal brief jerky movements involving his trunk and limbs, with recurrent falls for 10 months. We present here a case of heteroplasmic mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome with A3251G mutation, in which the clinical picture was dominated by a host of involuntary abnormal movements including chorea-ballism, myoclonus, and oromandibular dystonia in a backdrop of cognitive decline, seizure, and stroke-like episode. A final diagnosis was established by muscle biopsy and genetic study. Haloperidol was administered to control the involuntary movements along with introduction of co-enzyme Q, besides symptomatic management for his focal seizures. Six months into follow-up his seizures and abnormal movements were controlled significantly with slight improvement of cognitive abilities. CONCLUSION: The dominance of hyperkinetic movements in the clinical scenario and the finding of a point mutation A3251G in MT-TL1 gene make this a rare presentation.


Assuntos
Antidiscinéticos/uso terapêutico , Coreia/diagnóstico , DNA Mitocondrial/genética , Haloperidol/uso terapêutico , Síndrome MELAS/diagnóstico , Mutação Puntual/genética , Adolescente , Coreia/genética , Coreia/fisiopatologia , Testes Genéticos , Humanos , Síndrome MELAS/tratamento farmacológico , Síndrome MELAS/genética , Síndrome MELAS/fisiopatologia , Masculino , Micronutrientes/uso terapêutico , Resultado do Tratamento , Ubiquinona/uso terapêutico
14.
Ital J Pediatr ; 45(1): 36, 2019 Mar 12.
Artigo em Inglês | MEDLINE | ID: mdl-30871574

RESUMO

BACKGROUND: Migraine is one of the most prevalent chronic pain manifestations of childhood. Despite the multitude of available treatments, parents are often concerned about chronic therapies and pediatricians have insufficient confidence in prescribing prophylactic drugs. Therefore, there is now growing interest for natural supplements used to control recurrent migraine headaches. Such approach may increase acceptance and adherence to long-term prophylaxis therapy in children. METHODS: This is an observational multicenter study performed in children (n = 91) with migraine, with (MO) or without aura (MA), or tension-type headache (TTH). A fixed-dose Andrographis paniculata, CoQ10, riboflavin, and magnesium, was administered for 16 weeks. Patients were evaluated at baseline (T0), at week 8 (T1) and at the end of treatment at week 16 (T2). A follow-up period occurred at week 20 (T3) and week 32 (T4). RESULTS: The herbal supplement significantly reduced the frequency of headaches in TTH patients during treatment period (T0: 11.97 + 1.92 vs T2: 5.13 + 1.93; p < 0.001) and the efficacy was maintained after 16 weeks of treatment withdrawal (T4: 4.46 + 1.75; p < 0.001 vs T0). The frequency of migraine attacks was also reduced in the MO group during treatment (T0: 9.70 + 0.96 vs T2: 4.03 + 0.75; p < 0.01) and after withdrawal (T4: 2.96 + 0.65; p < 0.01 vs T0). Conversely, MA patients showed reduction in migraine's frequency during treatment (T0: 8.74 + 1.91 vs T2: 3.78 + 2.02; p < 0.01) but not at the end of the study (T4: 5.57 + 3.31; p > 0.05 vs T0). TTH patients did not report significant improvement of pain intensity. A significant effect was observed in the MO group during treatment (T0: 3.06 + 0.11 vs T2: 2.14 + 0.19; p < 0.001) and after treatment withdrawal (T4: 2.20 + 0.21; p < 0.001 vs T0). Likewise, MA group showed a significant treatment effect (T0: 2.57 + 0.20 vs T2: 0.86 + 0.45; p < 0.001) and the efficacy persisted at the end of the study (T4: 1.00 + 0.58; p < 0.001 vs T0). CONCLUSION: This fixed-dose Tanacetum parthenium preparation improved headache frequency and pain intensity in children affected by TTH. Despite the main limits, this study supports the use of nutraceutical in pediatric headache/migraine.


Assuntos
Suplementos Nutricionais , Transtornos de Enxaqueca/tratamento farmacológico , Transtornos de Enxaqueca/prevenção & controle , Extratos Vegetais/uso terapêutico , Tanacetum parthenium , Adolescente , Análise de Variância , Criança , Estudos de Coortes , Feminino , Seguimentos , Saúde Holística , Humanos , Itália , Magnésio/uso terapêutico , Masculino , Medição da Dor , Plantas Medicinais , Estudos Prospectivos , Riboflavina/uso terapêutico , Medição de Risco , Índice de Gravidade de Doença , Estatísticas não Paramétricas , Cefaleia do Tipo Tensional/tratamento farmacológico , Cefaleia do Tipo Tensional/prevenção & controle , Resultado do Tratamento , Ubiquinona/análogos & derivados , Ubiquinona/uso terapêutico
15.
Oxid Med Cell Longev ; 2019: 8039694, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30881598

RESUMO

Aim: Pancreatic stellate cells (PSCs) play a pivotal role in pancreatic fibrosis. Any remedies that inhibit the activation of PSCs can be potential candidates for therapeutic strategies in pancreatic fibrosis-related pancreatic ductal adenocarcinoma (PDAC) and chronic pancreatitis (CP). Our study is aimed at exploring the protective effect of coenzyme Q10 (CoQ10) against pancreatic fibrosis. Methods: Pancreatic fibrosis was induced by 20% L-arginine (250 mg/100 g) at 1 h intervals twice per week for 8 weeks in C57BL/6 mice. CoQ10 was administered for 4 weeks. Isolated primary PSCs from C57BL/6 mice were treated with 100 µM CoQ10 for 72 h, as well as Rosup and specific inhibitors. The effects of CoQ10 on the activation of PSCs, autophagy, collagen deposition, histological changes, and oxidative stress were analyzed by western blotting, biochemical estimations, immunofluorescence staining, and hematoxylin-eosin, Masson, and Sirius red staining, as well as with a reactive oxygen species (ROS) assay. Results: Pretreatment and posttreatment of CoQ10 decreased autophagy, activation of PSCs, oxidative stress, histological changes, and collagen deposition in the CP mouse model. In primary PSCs, expression levels of p-PI3K, p-AKT, and p-mTOR were upregulated with CoQ10. A rescue experiment using specific inhibitors of the PI3K-AKT-mTOR pathway demonstrated that the PI3K-AKT-mTOR signaling pathway was the underlying mechanism by which CoQ10 ameliorated fibrosis. With the addition of Rosup, expression levels of the autophagy biomarkers LC3 and Atg5 were elevated. Meanwhile, the levels of p-PI3K, p-AKT, and p-mTOR were lower. Conclusions: Our findings demonstrated that CoQ10 alleviates pancreatic fibrosis by the ROS-triggered PI3K/AKT/mTOR signaling pathway. CoQ10 may be a therapeutic candidate for antifibrotic methods.


Assuntos
Fibrose/tratamento farmacológico , Neoplasias Pancreáticas/tratamento farmacológico , Serina-Treonina Quinases TOR/uso terapêutico , Ubiquinona/análogos & derivados , Animais , Humanos , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Espécies Reativas de Oxigênio , Serina-Treonina Quinases TOR/farmacologia , Ubiquinona/farmacologia , Ubiquinona/uso terapêutico
16.
BMJ Case Rep ; 12(3)2019 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-30826776

RESUMO

A patient with Dupuytren's disease noted progressive disappearance of the contractures of both hands over a 3-year period while taking coenzyme Q10 daily for an unrelated condition. The function and appearance of his hands were restored to almost normal.


Assuntos
Suplementos Nutricionais , Contratura de Dupuytren/terapia , Ubiquinona/análogos & derivados , Vitaminas/uso terapêutico , Contratura de Dupuytren/fisiopatologia , Mãos/fisiopatologia , Humanos , Masculino , Pessoa de Meia-Idade , Ubiquinona/uso terapêutico
17.
Acta Neurol Scand ; 139(6): 533-539, 2019 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-30887496

RESUMO

OBJECTIVES: Friedreich's ataxia is the most common inherited ataxia, and pathogenesis is known to involve mitochondrial oxidative stress. Idebenone is a potent antioxidant which has already been evaluated in several clinical trials in FRDA, with reports of symptomatic benefit but inconclusive objective results. Following patient consultation on design, we have completed a treatment-withdrawal study to establish whether patients could correctly determine their treatment allocation to placebo or idebenone. Our aim was to capture subjective experiences of symptoms such as fatigue, which can be difficult to measure with questionnaires or semi-quantitative scales, particularly in chronic, slowly progressive conditions. MATERIALS AND METHODS: Patients taking idebenone for at least 12 months as part of the open-label MICONOS Extension Study were randomized to receive either placebo or idebenone continuation for 2-month treatment cycles. The primary endpoint was patient assessment of treatment assignment. RESULTS: A total of 29 patients were randomized, forming the idebenone group (n = 16) and the placebo group (n = 13). No significant differences were detected between the idebenone and placebo groups on assessment of treatment assignment or early study withdrawal. A small but significant difference in ataxia rating scale scores was detected between treatment groups when considering ambulatory patients only. CONCLUSIONS: This study provides no data to suggest that FRDA patients could correctly determine their treatment assignment over a 2-month period. We hope that this study design will help inform future trials so that patients' experiences of symptoms are more reliably measured.


Assuntos
Antioxidantes/uso terapêutico , Ataxia de Friedreich/tratamento farmacológico , Medidas de Resultados Relatados pelo Paciente , Ubiquinona/análogos & derivados , Adulto , Método Duplo-Cego , Feminino , Humanos , Masculino , Ubiquinona/uso terapêutico
19.
Neurology ; 92(14): e1643-e1651, 2019 04 02.
Artigo em Inglês | MEDLINE | ID: mdl-30850442

RESUMO

OBJECTIVE: Most suicidality literature in Huntington disease (HD) is based on natural history studies or retrospective reviews, but reports on risk factors from clinical trials are limited. METHODS: We analyzed 609 participants from 2CARE, a randomized, double-blind, placebo-controlled clinical trial with up to 5 years of follow-up, for risk factors related to suicidality. The primary outcome variable was the time from randomization until the first occurrence of either suicidal ideation or attempt. We also considered time from randomization until the first suicide attempt as a secondary outcome variable. RESULTS: Depression, anxiety, bipolar disorder, antidepressant or anxiolytic use, and prior suicide attempt at baseline were associated with time to ideation or attempt. Baseline employment status, marital status, CAG repeat length, tetrabenazine use, and treatment assignment (coenzyme Q10 or placebo) were not associated with suicidality. Time-dependent variables from the Unified Huntington's Disease Rating Scale Behavioral Assessment were associated with time to suicidal ideation or attempt, driven mainly by items related to depressed mood, low self-esteem/guilt, anxiety, suicidal thoughts, irritability, and compulsions. Variables associated with time to suicide attempt alone were generally similar. CONCLUSION: These data suggest psychiatric comorbidities in HD are predictive of suicidal behavior while participating in clinical trials, reinforcing the importance of clinical surveillance and treatment towards lessening risk during participation and perhaps beyond. Designing a composite algorithm for early prediction of suicide attempts in HD may be of value, particularly given anticipated trials aimed at disease modification are likely to be long-term. CLINICALTRIALSGOV IDENTIFIER: NCT00608881.


Assuntos
Doença de Huntington/epidemiologia , Ideação Suicida , Tentativa de Suicídio/estatística & dados numéricos , Inibidores da Captação Adrenérgica/uso terapêutico , Adulto , Ansiolíticos/uso terapêutico , Antidepressivos/uso terapêutico , Transtornos de Ansiedade/tratamento farmacológico , Transtornos de Ansiedade/epidemiologia , Transtorno Bipolar/epidemiologia , Transtorno Depressivo/tratamento farmacológico , Transtorno Depressivo/epidemiologia , Emprego , Feminino , Humanos , Proteína Huntingtina/genética , Doença de Huntington/tratamento farmacológico , Doença de Huntington/psicologia , Masculino , Estado Civil , Pessoa de Meia-Idade , Ensaios Clínicos Controlados Aleatórios como Assunto , Fatores de Risco , Tetrabenazina/uso terapêutico , Expansão das Repetições de Trinucleotídeos , Ubiquinona/análogos & derivados , Ubiquinona/uso terapêutico , Vitaminas/uso terapêutico
20.
J Fr Ophtalmol ; 42(3): 269-275, 2019 Mar.
Artigo em Francês | MEDLINE | ID: mdl-30712826

RESUMO

INTRODUCTION: Leber's Hereditary Optic Neuropathy (LHON) causes a rapid and severe decrease in visual acuity. Raxone® (Idebenone, Santhera) is the only drug to have a European Marketing Authorization for the treatment of this optic neuropathy. It can be proposed in the first months after the onset of this optic neuropathy, according to an international consensus meeting. PATIENTS AND METHODS: Retrospective study of the efficacy of Raxone® on the visual acuity of patients with genetically confirmed LHON who were followed in four Parisian hospitals. The primary endpoint is the best recovery of LogMar visual acuity between baseline and the end of follow-up. The secondary endpoints are the evolution of LogMar visual acuity of the best eye at baseline and change in LogMar visual acuity for each eye considered separately. RESULTS: Seventeen patients, three women and 14 men, mean age 34.2 years, naive to treatment with Raxone® were included in this study. The mean duration of treatment was 11.0±6.6 months. A mitochondrial DNA mutation was found in all patients. Only 2 had the 14484 mutation. A recovery of better LogMar visual acuity was found at the end of the treatment for 4 eyes (23.5 %), and a deterioration was observed for 8 (47.0 %). Only 2 eyes (11.7 %) with the best visual acuity at baseline improved. On the other hand, 17.6 % of the eyes considered separately had an improvement in their LogMar visual acuity at the end of the treatment. CONCLUSION: The results confirm the trend of Raxone® treatment to improve patients' visual acuity. Given the recommendations of a consensus conference, this treatment should be started early after the onset of LHON. It is therefore important to look for this diagnosis in the presence of any hereditary optic neuropathy, in order to be able to initiate this treatment.


Assuntos
Atrofia Óptica Hereditária de Leber/tratamento farmacológico , Ubiquinona/análogos & derivados , Adolescente , Adulto , Progressão da Doença , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Atrofia Óptica Hereditária de Leber/patologia , Atrofia Óptica Hereditária de Leber/fisiopatologia , Paris , Estudos Retrospectivos , Resultado do Tratamento , Ubiquinona/uso terapêutico , Acuidade Visual/efeitos dos fármacos , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA